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Abstract Brefeldin A (BFA) is a potent inhibitor of intracellular 
vesicle traffic. We have investigated the effects of BFA on the 
traffic of the insulin receptor in HIRcB cells, a cell line derived 
from Rat-1 fibroblasts that over-expresses a normal human insu- 
lin receptor. We report here that insulin-dependent receptor edis- 
tribution is inhibited by BFA and that this drug has no effects on 
the insulin-independent redistribution of the receptor. Auto- 
phosphorylation of the insulin receptor and the stimulation of 
mitogen-activated protein kinase (MAPK) by insulin were not 
affected by treatment with the drug. The effects of BFA were 
further shown to require addition of the drug prior to the addition 
of insulin. BFA added 10 rain after stimulation with insulin had 
no effects on the redistribution of the receptor. Dose-response 
studies demonstrated that the effects of BFA were half-maximal 
at a dose of 1 ttglml and maximal at about 10 pg/ml. These 
findings suggest hat BFA blocks an early step in the chain of 
events that lead to insulin receptor internalization without affect- 
ing the interactions of the receptor with insulin, the stimulation 
of the tyrosine kinase activity of the receptor by the hormone, or 
other insulin-regulated signalling pathways, such as the activation 
of MAPK. 
Key words. Brefeldin A; Insulin; Receptor; Endocytosis 
I. Introduction 
The insulin receptor (IR) is a heterotetrameric protein com- 
posed of two extracellular ~-subunits and two transmembrane 
fl-subunits [1]. Insulin binds to the ~-subunits and initiates a
chain of events that results in the autophosphorylation of the 
fl-subunits and other intracellular substrates [2,3]. Stimulation 
of the tyrosine kinase activity of the receptor appears to be 
crucial to most biological effects of insulin [4-6]. One of the 
consequences of the binding of insulin to the receptor is the 
stimulation of the internalization of the hormone-receptor 
complex [7,8]. Internalization of this complex results in the 
degradation ofthe hormone [9-12]. Unliganded receptor isthen 
recycled back to the surface of the cell or further degraded [13]. 
The internalization f the IR in HIRcB cells and other cell 
lines derived from Rat-1 fibroblasts has been extensively stud- 
ied in recent years by ultrastructural nd biochemical tech- 
niques [4,14-16]. Two independent pathways appear to exist in 
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receptor-mediated insulin internalization: an ATP-dependent 
concentrative process using coated pits on the cell surface, and 
an ATP-independent process that uses non-coated plasma 
membrane invaginations [14]. The proportion of IR internaliza- 
tion by either pathway is ligand concentration dependent 
[14,16]. Coated pit-mediated internalization proceeds by a 
mechanism that involves everal distinct steps: aggregation on 
the cell surface, migration to the coated pits and internalization 
[13,14]. Tyrosine kinase-deficient receptors were shown to ag- 
gregate normally but failed to concentrate in the coated pits and 
were not internalized [14]. The alternative, ATP-independent 
pathway of IR internalization has not been described in detail. 
The isoprenoid fungal metabolite brefeldin A (BFA) is a 
potent inhibitor of intracellular vesicle assembly and traffic 
[17-20]. The effects of BFA include the disappearance of non- 
clathrin-coated buds and transport vesicles, the inhibition of 
constitutive secretion, and changes in the structure and func- 
tion of organelles associated tothe endocytic and exocytic path- 
ways [17-20]. In spite of these remarkable ffects on vesicle 
trafficking, BFA has not been shown to inhibit receptor-medi- 
ated endocytosis [21,22]. However, the effects of BFA on the 
internalization a d processing of tyrosine kinase receptors have 
not been studied to date. Given the extensive work carried out 
in the characterization f the mechanisms of internalization f 
the insulin receptor in the Rat-1 fibroblast model [14-16,23], we 
decided to investigate he effects of BFA on the internalization 
of the insulin receptor in HIRcB cells. We report here that BFA 
blocks the insulin-dependent redistribution f the insulin recep- 
tor in a dose-dependent manner without affecting insulin recep- 
tor autophosphorylation or other signalling pathways associ- 
ated to insulin, such as MAPK activation. We also show that 
the blockade of insulin-induced receptor redistribution requires 
addition of the toxin prior to exposure to insulin, suggesting 
that BFA's effects take place at a very early event during the 
generation of the signals that lead to receptor internalization. 
2. Experimental 
2.1. Cell culture conditions 
HIRcB cells were a gift of Dr. D. McClain. These cells are derived 
from Rat-1 fibroblasts and over-express the human insulin receptor at 
very high levels (about 106 receptors/cell). Cells were cultured in 10 or 
6 cm dishes using DMEM/F12 supplemented with 10% FBS and 
100 nM methotrexate s described [4]. Cells were used within 5 days of 
subculture and were serum starved for 20 h in medium containing 0.1% 
BSA before treatment. These conditions maximize the levels of expres- 
sion of insulin receptors on the surface of the cell and minimize basal 
levels of activity in terms of receptor autophosphorylation and MAP 
kinase activity. 
2.2. Treatment with &sulin and brefeldin A 
Serum-starved cells were washed twice with fresh medium and incu- 
bated with BFA (3 or 10/tg/ml) for up to 15 min before the addition 
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of insulin. Cells were treated with insulin (20-100 nM) at 37°C in 
serum-free medium supplemented with 0.1% BSA. 
2.3. Redistribution of the insulin receptor 
The redistribution of insulin receptors was studied by a procedure 
based on the use of specific monoclonal antibodies that recognize the 
c~- and fl-subunits of the receptor. Internalized receptors were distin- 
guished from those present on the cell surface on the basis of their 
sensitivity to mild trypsin treatment of the cells, as originally described 
by Levy and Olefsky [24], a procedure that has been used as a tool to 
distinguish cell surface from internalized receptors [4,23-26]. Mild tryp- 
sin treatment (1mg/ml trypsin for 30 min at 4°C) cleaves the ~-subunit 
of the receptor predominantly at one site, releasing two fragments: a 
100 kDa fragment that contains the binding sites for insulin and for the 
monoclonal antibody 83-7, and a 20 kDa fragment that remains at- 
tached to the fl-subunit [27]. Thus, the criterion used to detect intact 
receptors was the co-immunoprecipitation of c~- and fl-subunits: only 
those fl-subunits attached to intact, non-proteolyzed c~-subunits co- 
immunoprecipitate with mAb 83-7. 
HIRcB cells were cultured as described above in 6 cm plates until 
confluent and serum starved overnight before use. Where indicated, 20 
or 100 nM insulin and 3/2g/ml BFA were added to the plates for 30 min 
at 37°C. The cells were washed with PBS and DMEM/0.1% BSA (pH 
4.0) to eliminate surface-bound insulin, and treated with trypsin (1 rag/ 
ml) at 4°C for 30 min. Trypsin treatment was stopped by addition of 
0.1 ml of a solution containing 0.4% Triton X-100, 25 mg/ml soybean 
trypsin inhibitor, 5 mg/ml bacitracin, 100/2g/ml leupeptin. Cells were 
solubilized in this medium for 20 min, and insoluble material removed 
by centrifugation. Antibody 83-7 (HIR ~-subunit specific) was immobi- 
lized using goat anti-mouse IgG-agarose by incubation of hybridoma 
culture supernatants with the resin for 2 h followed by removal of 
unbound antibody by washing with PBS. Solubilized insulin receptors 
were immunoprecipitated by overnight incubation at 4°C with immobi- 
lized mAb 83-7. Insulin binding to the imrnunoprecipitated material 
was determined with [~25I]insulin (control experiments demonstrated 
that the insulin binding capacity of the immunoprecipitated r ceptors 
was not affected by trypsin treatment under the conditions described). 
The samples were then analyzed by SDS-PAGE and immunoblotted 
with either mAb CT-1 (IR fl-subunit specific) or mAb 4G10 (anti- 
phosphotyrosine specific). A chemiluminescent method was used to 
detect he bound antibody, taking the precaution to adjust he exposure 
to within a linear response range as determined with a set of standards. 
The intensity of the 95 kDa band corresponding to the fl-subunit of the 
insulin receptor was determined by densitometry and normalized to the 
insulin binding capacity of the immunoprecipitate. 
2.4. Insulin binding 
To validate the trypsin digestion/immunoprecipitation pr cedure 
used, the binding of insulin to the immunoprecipitated material was 
determined by standard competition binding procedures. Immunopre- 
cipitated receptors were incubated with [~25I]insulin (0.1 nM) in the 
presence of increasing concentrations of unlabelled insulin (0.1-100 
nM) for 1 h at room temperature in 50 mM HEPES (pH 7.5) containing 
1 mM EDTA, 1 mM EGTA and 1 mg/ml bacitracin. Non-specific 
binding was determined in the presence of l0/2M unlabelled insulin. 
At the end of the incubation, the immunoprecipitated material was 
washed 4 times with immunoprecipitation buffer. Bound insulin was 
determined by gamma counting. Quantitation of insulin binding for the 
normalization of individual samples was carried out as follows. The 
immunoprecipitated material was divided into 3 equal parts and radio- 
labelled insulin was added to each to a final concentration f 0.1 nM. 
Unlabelled insulin was added to two of the samples (final concentra- 
tions: 2 nM and 10/2M, respectively). Binding was estimated as de- 
scribed above. Non-specific binding was estimated from the sample 
containing 10 uM unlabelled insulin. The samples were recovered after 
counting, boiled with Laemmli sample buffer and used to run the 
SDS-PAGE procedures described above to quantitative the levels of 
HIR fl-subunits co-precipitating with the insulin binding activity. 
2.5. Tyrosine phosphorylation of the insulin receptor 
Autophosphorylation of the receptor was determined using material 
immunoprecipitated with 83-7 mAb. Briefly, the immunoprecipitates 
were resolved by SDS-PAGE in 9% acrylamide gels, blotted onto nitro- 
cellulose, and phosphotyrosine-containing proteins were detected by 
immunoblotting using mAb 4G10. 
2.6. MAPK activity 
MAPK activity was determined using whole cell lysates after frac- 
tionation of the samples using FPLC procedures as described by Dent 
et al. [28]. Cells were solubilized in 50 mM HEPES (pH 7.5) containing 
1% Triton X-100, 25 mM Na-fluoride, 2 mM Na-vanadate, 1 mM 
p-nitrophenylphosphate, 2/.tg/ml eupeptin, 1 mg/ml soybean trypsin 
inhibitor, and 1 mM PMSF. After removal of the insoluble material by 
centrifugation, the equivalent of 1 mg of cell protein was fractionated 
by FPLC using a Mono Q ion-exchange column and a 0.1-0.3 M NaCI 
gradient. All samples were assayed for protein kinase activity using 
myelin basic protein (2 mg/ml) as a substrate and 100/tM [~'-32P]ATP 
as the phosphate donor. 
2. 7. Other procedures 
Protein concentrations were determined using a commercial kit 
(BCA assay, from Pierce). Chemiluminescence d tection of protein 
bands in immunoblots was carried out as described by the manufac- 
turer of the kit (Renaissance; NEN/Dupont). 
2.8. Materials 
Monoclonal antibodies 83-7 and CT-1, originally produced and char- 
acterized in the laboratory of Dr. K. Siddle, were a gift of Dr. Peter 
Isakson (Monsanto). These antibodies have been extensively described 
by Clark et al. [27]. Anti-phosphotyrosine antibody 4GI0 was pur- 
chased from Upstate Biotechnologies. Brefeldin A was purchased from 
Boehringer. ~25I-Labelled insulin and [y-32p]ATP were obtained from 
New England Nuclear. All other reagents were supplied by Sigma 
Chemical Co. 
3. Results 
The distribution of the insulin receptor (IR) between the cell 
surface and intracellular compartments was determined by ex- 
posure of cells to mild trypsin (1 mg/ml) treatment at 4°C for 
30 min. As reported by other investigators, only receptors ex- 
posed to the extracellular medium are accessible to trypsin 
[4,23 26]. This treatment proteolyzes the ~-subunit of the re- 
ceptor in a unique site close to the C-terminus of the ~-subunit 
and separates both subunits [27]. The larger fragment resulting 
from this treatment (100 kDa) contains both the mAb 83-7 and 
insulin binding sites, whereas the smaller fragment remains 
attached to the fl-subunit of the receptor [27]. In agreement with 
this, we observed that mild trypsin treatment of the intact cells 
did not quantitatively alter the insulin binding capacity of the 
material precipitated with mAb 83-7: the total immunoprecip- 
itable insulin binding activity from trypsinized cells was 
112.2+ 14% of the total obtained from untreated cells 
(mean + S.D., n = 8 cell plates in each group). In contrast, 
trypsin treatment had a very significant effect in the amount  of 
receptor fl-subunits co-precipitated with the c~-subunits (Fig. 1). 
This is consistent with the work of Clark et al., who suggested 
that mild trypsin treatment leaves the ~-subunit of the receptor 
substantially intact [27]. Fig. 1 shows that treatment with 20 nM 
insulin increases the number of trypsin-resistant IR by about 
3-fold. BFA abolished the effects of insulin on the redistribu- 
tion of IR. In the absence of insulin the distribution of H IR  was 
not affected by BFA. 
The time~zourse of the insulin-dependent redistribution of 
the IR is shown in Fig. 2a. The levels of trypsin-insensitive 
receptors increased with time, reaching a maximum at about 
30 min. Addit ion of BFA 5 min prior to insulin blocked redis- 
tr ibution of the receptor. Identical effects were observed with 
the addition of BFA 10 or 15 min before insulin (not shown). 
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However, when insulin was added before BFA (Fig. 2b) the 
effects of the toxin were negligible. Fig. 2c shows the time- 
course of the internalization of the IR using anti-phosphoty- 
rosine (mAb 4G10) antibodies to detect the tyrosine- 
phosphorylated fl-subunit. The data obtained with mAb 4G 10 
were qualitatively very similar to those obtained with mAb 
CT-1, an observation that further supports the validity of the 
procedure used. These data and the data shown in Fig. 2d also 
demonstrate hat BFA has no effect on the phosphorylation r 
dephosphorylation of the IR. We suggest, hus, that BFA inter- 
feres with an early event in the insulin signalling pathway lead- 
ing to the internalization of the receptor, that this early event 
is not the auto-phosphorylation of the receptor, and that, once 
the initial signalling event hat leads to receptor internalization 
has occurred, BFA has no further effects on the receptor redis- 
tribution process. 
In order to determine whether or not the effects of BFA were 
confined to the redistribution of the IR, we also studied the 
effects of BFA on other insulin-regulated functions, such as the 
insulin-stimulated activation of MAPK. MAPK activation was 
not affected by preincubation of the cells with 5 pg/ml BFA. 
The MAPK activity, expressed as nmol of 32p incorporated into 
protein per 60 min per mg of cell protein, was as follows: 
control, 4.56 + 0.95; 5 /IM BFA, 5.5 + 1.1; 100 nM insulin, 
29.2 + 9.6; 100 nM insulin + 5 /.tM BFA, 31.2 + 7.5 
(mean + S.E.M., n -- 3). This suggests that receptor traffic and 
the activation of MAPK are regulated by intracellular signals 
that diverge arly on in the signalling cascade initiated by insu- 
lin. 
The insulin dose dependence of the redistribution of the 
receptor is shown in Fig. 3a and b. In these experiments, cells 
were stimulated with insulin at various concentrations for 
30 min and the levels of trypsin-insensitive receptors were mon- 
itored as described. Typical results are shown in Fig. 3a (lanes 
1 5). The data were analyzed by densitometry, normalized as 
described and summarized in Fig. 3b. As shown, the effect of 
insulin was half-maximal between 1and 10 nM, consistent with 
the dose dependence of most insulin-modulated processes. The 
effects of BFA at maximal insulin concentrations (100 nM) are 
shown in Fig. 3a (lanes 6-11) and Fig. 3c. The half-maximal 
inhibitory dose was about 1 ~tg/ml, and complete inhibition of 
the insulin-induced redistribution of the receptor is observed at 
10/tg/ml. These figures correlate very well with the concentra- 
tions of BFA necessary to disrupt assembly of the Golgi appa- 
ratus [19]. These observations were repeated 3 times with 2 in- 
dependent lots of BFA and some lot-to-lot variations were 
observed. The correlation between the levels of BFA required 
to disrupt he Golgi and those found to inhibit IR internaliza- 
tion suggests a similar cause for both effects. 
4. Discussion 
The data we have presented in this paper demonstrate hat 
short exposure to BFA does not affect the surface levels of IR, 
whereas exposure to insulin increases the levels of receptors in 
intracellular pools by about 3-fold. However, when cells are 
exposed to BFA prior to the addition of insulin, the effects of 
the hormone on the redistribution of the receptor are blocked. 
There are, in principle, three cellular events related to the insu- 
lin-induced surface redistribution of the IR that might be af- 
fected by BFA treatment. These are: (i) the internalization of 
the receptor; (ii) the recycling of internalized receptors to the 
surface of the cell; and (iii) the signalling mechanisms by which 
insulin modulates receptor internalization and/or recycling. 
The data shown in Figs. 1 and 2 provide significant support o 
the hypothesis that BFA interferes with the generation of an 
insulin-dependent signal rather than with receptor internaliza- 
tion or recycling processes per se. If the effects of BFA were 
related mainly to the processes involved in receptor internaliza- 
tion and/or recycling, BFA would be expected to alter the 
surface distribution of the receptor in the absence of stimula- 
tion by insulin, as shown for the IGF-I I  receptor [21]. Further- 
more, Fig. 2a shows that if the effects of BFA were reduced to 
the inhibition of receptor traffic, then BFA should block recep- 
tor internalization, greatly accelerate the rate of recycling the 
receptor back to the surface or a combination of both proc- 
esses. However, addition of BFA 10 min after insulin had no 
effects on the insulin-induced redistribution of the receptor. 
Fig. 2a-c show that the receptor redistribution process had not 
reached a steady state at the time of addition of BFA when the 
drug was added after insulin. Therefore, both receptor internal- 
ization and recycling were still active processes at the time of 
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Fig. I. The effects of brefeldin A on the internalization of the insulin 
receptor. BFA (3/~g/ml) was added to the cells 5 min prior to the 
addition of insulin. Cells were stimulated with 100 nM insulin for 
30 min. (A) Representative xperiment performed as described. 
(B) Summary of data obtained (n = 9 different plates in two independ- 
ent sets of experiments for each treatment). ANOVA of the final results 
showed that the difference between insulin treatment alone and either 
control or insulin + BFA is significant (P < 0.01). As shown, BFA had 
no effects on the distribution of the receptor in unstimulated cells. 
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Fig. 2. (a) Time-course of the redistribution of the insulin receptor. These experiments were carried out as described in the legend for Fig. 1. The 
lower curve shows the effects of the addition of 3 pg/ml BFA 5 min before the addition of insulin. (b) Same as (a), with the exception that, when 
indicated (10 min after the addition of insulin), 3 ~g/ml BFA was added to one set of plates. (c) Time~zourse of the internalization of the receptor 
obtained as described in (b) using anti-PY antibodies (mAb 4GI0) to detect yrosine-phosphorylated receptor fl-subunits. (d) Cells were treated with 
insulin for 2 min where indicated and solubilized. For each condition, insulin receptors contained in 1 mg of cell lysate were precipitated with excess 
mAb 83-7 (see section 2). Therefore, equivalent amounts of receptor protein were analyzed. Samples were analyzed by SDS-PAGE and blotted. Blots 
were developed with anti-PY antibodies (mAb 4G10). 
addition of the inhibitor. If BFA's effects were related to gen- 
eral, non-specific hanges in the machinery of receptor traffick- 
ing, addition of BFA after initiation of the insulin-modulated 
events that lead to the redistribution of the receptor should 
have the same effects as addition of  BFA before insulin. Thus, 
BFA would be expected to stop the internalization process, to 
accelerate the recycling process, or a combination of both. 
However, our data show that receptor edistribution was insen- 
sitive to the addition of BFA when the drug was added after 
stimulation of the cells with insulin. We suggest herefore that: 
(i) BFA's main effects in the receptor edistribution phenome- 
non are not due to the action of the drug on receptor internal- 
ization or recycling per se; (ii) BFA interferes with the signalling 
process by which insulin binding to the receptor modulates the 
subcellular distribution of receptors; and (iii) once receptor 
redistribution is triggered, BFA cannot interfere with the 
process. 
It should be noted that BFA, in spite of its major effects on 
multiple membrane assembly and trafficking processes, has not 
been previously shown to inhibit receptor-mediated ndocyto- 
sis. For instance, the IGF- I I  receptor in fibroblasts [21] and the 
transferrin receptor in epithelial cells [22] are internalized by 
processes that involve aggregation and accumulation in 
clathrin-coated pits but neither process is affected by BFA. 
Furthermore, it has been reasonably well established that al- 
though BFA causes the complete dispersion of Golgi-derived 
clathrin lattices it does not affect the assembly or function of 
clathrin-coated vesicles derived from the plasma membrane 
[34,35]. Thus, although the molecular basis for the BFA sensi- 
tivity of the IR internalization process is not clear at this time, 
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Fig. 3. Internalization of the insulin receptor as a function of the 
concentrations of insulin and BFA. (A) Western blot showing the levels 
of trypsin-resistant insulin receptors. Cells were treated with increasing 
concentrations of insulin (lane 1, untreated; lane 2, 0.1 nM insulin; lane 
3, 1 nM insulin; lane 4, 10 nM insulin; lane 5, 100 nM insulin) or in the 
presence ofBFA (lanes 6-11:100 nM insulin, supplemented with: lane 
6, 0.l ¢tg/ml BFA; lane 7, 0.3 pg/ml BFA; lane 8, 1 ¢tg/ml BFA; lane 
9, 3 pg/ml BFA; lane 10, 10 ¢tg/ml BFA; and lane 11, 30 pg/ml BFA). 
The insulin receptors were precipitated with mAb 83-7 and the fl- 
subunits detected with mAb CT-1 as described in section 2. (B) Sum- 
mary of the data obtained by densitometry analysis of the blot shown 
in A, lanes 1 5. (C) Summary of the data obtained by densitometry 
analysis of A, lanes 6-11. 
it is likely that the BFA-sensitive vent precedes the assembly 
of the clathrin-coated vesicles. It should also be noted that IR 
internalization may occur by a second mechanism that does not 
involve clathrin coats, particularly at insulin concentrations i  
the nanomolar range, such as those used in our work [16]. BFA 
may interfere primarily with this mechanism, and not with the 
classical clathrin-coated pit system. 
The mechanisms by which the endocytic apparatus detects 
the state of occupancy of the IR are not understood. Ultra- 
structural studies carried out with Rat-1 fibroblasts that over- 
express normal and tyrosine kinase-deficient IR have shown 
that receptor aggregation per se is insufficient to trigger the 
internalization process [14]. IR internalization appears to re- 
quire intact tyrosine kinase activity of the receptor fl-subunit. 
This suggests that the signal that triggers internalization rigi- 
nates with the phosphorylation of some intracellular target. 
Our data show that BFA blocks IR internalization without 
altering the state of tyrosine phosphorylation f the receptor 
or the phosphorylation f the cellular targets that lead to the 
activation of MAPK. The question of what is the BFA-sensitive 
biochemical event in the mechanism ofinternalization f the IR 
thus remains unanswered. It should be noted that the only 
reasonably well-characterized biochemical effect of BFA is the 
blockade of the activation of small G proteins of the ADP- 
ribosylation factor (ARF) family, a class of small G proteins 
involved in many aspects of intracellular membrane traffic and 
assembly [29 33]. A potential scenario that derives from the 
observations reported here is one in which binding of insulin 
to the receptor leads to the activation of a member of the ARF 
family of G proteins and that this phenomenon is required for 
the activation of the internalization process. Work currently 
under way in our laboratory suggests that insulin can indeed 
stimulate the activation of ARF proteins in a reconstitution 
assay (K. Shome and G. Romero, in preparation). These find- 
ings, taken altogether, suggest that the internalization f the IR 
proceeds by a novel mechanism that involves a BFA-sensitive 
event, possibly the activation of a small G protein of the ARF 
family. We would also like to point out that after the initial 
submission of this manuscript evidence indicative of the in- 
volvement of a BFA-sensitive step in the mechanism by which 
insulin stimulates the recruitment of GLUT4 glucose trans- 
porters to the surface of rat adipocytes was reported by Lachaal 
et al. [36]. These findings, taken in conjunction with the data 
presented here, suggest that a BFA-sensitive vent is required 
for the generation of insulin-mediated signals that modulate 
membrane trafficking processes. 
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